Cipla announced a commercial collaboration with UK-based S&D Pharma to distribute its products in the Czech Republic and Slovakia.

Commenting on the results, Sarabjit Kour Nangra, VP Research, IT, Angel Broking, said, ''Under the collaboration, it will sell its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla-owned sales force managed by its commercial head while S&D Pharma will physically distribute all products, including respiratory products. This portfolio is expected to increase in the next few years.
 
The development is positive from long term perspective for the respiratory franchisee of the company, however on back of valuations, we remain neutral on the stock.''

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.